New mineralocorticoid-receptor antagonist passes in phase 2 study

Patients treated with the drug, known only as BAY94-8862 at the moment, had a significantly lower risk of hyperkalemia than patients treated with spironolactone, as well as a lower risk of worsening renal failure. The drug also reduced BNP levels as much as spironolactone.
Source: theHeart.org - Category: Cardiology Source Type: news